Navigation Links
Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Date:7/29/2008

ble programs. The most advanced compounds in development include VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and the octreotide implant for acromegaly.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
2. Indevus Announces Management Changes
3. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
4. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
5. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
6. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
7. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
8. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
9. Indevus Announces Allergan as New Partner for SANCTURA Brand
10. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
11. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
(Date:5/23/2013)... 23, 2013 BioTrends Research Group, one ... for specialized biopharmaceutical issues, finds that, unaided, one ... specialists reported that in the past six months, ... treatment) in anticipation of the next generation of ... when only 6 percent reported that they had ...
(Date:5/23/2013)... The New Jersey chapter of the largest organization ... (BDPA), is hosting its 10th annual Families in Technology ... will encourage students and their parents to explore the ... many of the industries’ finest teachers. Held from 9 ... of Technology, the event will include workshops, instruction and ...
(Date:5/23/2013)... , May 23, 2013 Pusan National ... a private biotherapeutics and contract research company focused ... for cancer, announced today a publication reporting the ... with the oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene ... was published in the May 15 th , ...
Breaking Biology Technology:Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... focused on commercialization of ColonSentry(TM); Asian resources ... - TORONTO, Nov. 12 /PRNewswire-FirstCall/ - GeneNews ... biomarker tests for the early,detection of diseases and ... a strategic restructuring of its North American and,Asian ...
... ... Association ... http://www.nicox.com , SOPHIA ANTIPOLIS, France, November 12 NicOx,S.A. (Euronext Paris: COX) today ... (ABPM) study for,naproxcinod was presented yesterday at the American Heart Association,Scientific Sessions 2008, in ...
... Sanofi Pasteur and Chumakov Institute Russian Academy Medical Sciences, ... Russia ... National "Project Health", PARIS, November 12 ... that Russia has,chosen inactivated polio vaccine (IPV) from Sanofi Pasteur ...
Cached Biology Technology:GeneNews restructures operations 2GeneNews restructures operations 3NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen 2NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen 3Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 2Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 3Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 4Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 5Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 6
(Date:5/21/2013)... a whale entangled in fishing gear, scientists showed for ... diving and swimming behavior. The monitoring revealed how fishing ... their energy as they drag gear for months or ... The scientists in this entanglement response suction-cupped a cellphone-size ... Atlantic right whale called Eg 3911. The Dtag, developed ...
(Date:5/21/2013)... class of pharmaceuticals can both prevent and treat Alzheimer,s ... "TSPO ligands," are currently used for certain types of ... ligand in young adult mice when pathology was at ... was quite severe," said lead researcher Christian Pike of ... measures of pathology and improved behavior at both ages." ...
(Date:5/21/2013)... pharmacies and health stores, phosphatidylserine is a natural ... Proven to improve cognition and slow memory loss, ... memory impairment. Now a team headed by Prof. ... Aviv University,s Department of Human Molecular Genetics ... the functioning of genes involved in degenerative brain ...
Breaking Biology News(10 mins):Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3Drugs found to both prevent and treat Alzheimer's disease in mice 2Common food supplement fights degenerative brain disorders 2
... Kingston, ON A new approach to tracking ... more light on the potentially endangered Arctic animal and ... Integrating the traditional knowledge of Inuit hunters with state-of-the-art ... Peter V.C. de Groot and Peter Boag, is cheaper ...
... CORVALLIS, Ore. Researchers at Oregon State University recently completed ... toxicology, and the findings challenge some basic concepts about how ... considered safe. The study found that acceptable levels of ... higher than is currently believed. It also indicates that for ...
... SIB Swiss Institute of Bioinformatics and the Biozentrum of ... Biology Conference "Molecular Evolution", opened today at the Congress ... 200th birthday of Charles Darwin and the 150th anniversary ... Origin of the Species". Invited speakers include leading ...
Cached Biology News:New tracking approach will help protect polar bears 2Improved method developed to test carcinogen risk 2Improved method developed to test carcinogen risk 37th annual [BC]2 Basel Computational Biology Conference 'Molecular Evolution' June 18-19, 2009 27th annual [BC]2 Basel Computational Biology Conference 'Molecular Evolution' June 18-19, 2009 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
PURA Immunogen: PURA (NP_005850, 183 a.a. ~ 293 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: